Highlights from ESMOGI24 by Angela Lamarca
ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared some highlights from this conference:
Reflections by Digestive Cancers Europe
Reflections on how to increase patients involvement in shared decision making and clinical trials by Digestive Cancers Europe.
Not an easy task, but I agree: Trust between physicians and patients is key and good communication is the core of this trust.
ESMO supports gastrointestinal cancers
I think it was clear during ESMOGI24 that ESMO supports gastrointestinal cancers and Andres Cervantes made it clear in his closing remarks. Examples:
- ESMO Guidelines in GI
- Living guidelines
- MCBS
- Dedicated conference and journal
Outstanding Keynote lecture in HCC by Stephen Chan at ESMOGI24. So much done and so much to do. Systemic well stablished in advanced disease, now moving to early stage. I agree: most hot topic: neoadjuvant.
3-year OS data from TOPAZ-1 at ESMOGI24. More long survivors (>30m) in the Durva arm 17% vs 8.7% (DESPITE more subsequent therapies in placebo arm). Similar baseline characteristics (BUT more likely to be long survivor if had responded)- data?
Cell Therapy on Gastrointestinal Cancers
Kohei Shitara on Cell Therapy on Gastrointestinal Cancers at ESMOGI24:
- Many trials ongoing
- Balancing toxicity/activity
- CLDN and HER2 “recurrent” topics
Modulating microbiome in Gastrointestinal Cancers
Modulating microbiome in Gastrointestinal Cancers by Elena Elez at ESMOGI24. Evidence is supportive Bringing this to trials and clinical practice is very challenging. We will need to work with other specialist to become this a reality.
Immunotherapy in Gastrointestinal Cancers
Maximising Immunotherapy in Gastrointestinal Cancers at ESMOGI24 by Santiago Ponce.
- So much data and very much to learn
- So many options ahead for more research
- Step by step getting there
For more coverage on ESMOGI24, visit the OncoDaily website.